Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Rosalinde E. R. Slot; Sietske A. M. Sikkes; Johannes Berkhof; Henry Brodaty; Rachel Buckley; Enrica Cavedo; Efthimios Dardiotis; Francoise Guillo-Benarous; Harald Hampel; Nicole A. Kochan; Simone Lista; Tobias Luck; Paul Maruff; Jose Luis Molinuevo; Johannes Kornhuber; Barry Reisberg; Steffi G. Riedel-Heller; Shannon L. Risacher; Susanne Roehr; Perminder S. Sachdev; Nikolaos Scarmeas; Philip Scheltens; Melanie B. Shulman; Andrew J. Saykin; Sander C. J. Verfaillie; Pieter Jelle Visser; Stephanie J. B. Vos; Michael Wagner; Steffen Wolfsgruber; Frank Jessen; Wiesje M. van der Flier; Alzheimer's Disease Neuroimaging Initiative; DESCRIPA working group; Insight-PreAD Study Grp; SCD‐I working group

doi:10.1016/j.jalz.2018.10.003

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Rosalinde E. R. Slot, Sietske A. M. Sikkes, Johannes Berkhof, Henry Brodaty, Rachel Buckley, Enrica Cavedo, Efthimios Dardiotis, Francoise Guillo-Benarous, Harald Hampel, Nicole A. Kochan, Simone Lista, Tobias Luck, Paul Maruff, Jose Luis Molinuevo, Johannes Kornhuber, Barry Reisberg, Steffi G. Riedel-Heller, Shannon L. Risacher, Susanne Roehr, Perminder S. SachdevNikolaos Scarmeas, Philip Scheltens, Melanie B. Shulman, Andrew J. Saykin, Sander C. J. Verfaillie, Pieter Jelle Visser, Stephanie J. B. Vos, Michael Wagner, Steffen Wolfsgruber, Frank Jessen, Wiesje M. van der Flier^*, Alzheimer's Disease Neuroimaging Initiative, DESCRIPA working group, Insight-PreAD Study Grp, SCD‐I working group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia.

Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models.

Results: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini-Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E epsilon 4 (1.8 [1.3-2.5]) increased the risk of dementia.

Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts. (C) 2018 The Authors. Published by Elsevier Inc.

Original language	English
Pages (from-to)	465-476
Number of pages	12
Journal	Alzheimer's & Dementia
Volume	15
Issue number	3
DOIs	https://doi.org/10.1016/j.jalz.2018.10.003
Publication status	Published - Mar 2019

Keywords

Subjective cognitive decline
Dementia incidence
Preclinical Alzheimer's disease
Alzheimer's disease
Vascular dementia
Frontotemporal dementia
Dementia Lewy bodies
BASE-LINE CHARACTERISTICS
MEMORY COMPLAINTS
ASSOCIATION WORKGROUPS
DIAGNOSTIC GUIDELINES
NATIONAL INSTITUTE
RECRUITMENT METHODS
APOLIPOPROTEIN-E
MAJOR SUBTYPES
OLDER-ADULTS
IMPAIRMENT

Access to Document

10.1016/j.jalz.2018.10.003Licence: CC BY-NC-ND

Cite this

Slot, R. E. R., Sikkes, S. A. M., Berkhof, J., Brodaty, H., Buckley, R., Cavedo, E., Dardiotis, E., Guillo-Benarous, F., Hampel, H., Kochan, N. A., Lista, S., Luck, T., Maruff, P., Molinuevo, J. L., Kornhuber, J., Reisberg, B., Riedel-Heller, S. G., Risacher, S. L., Roehr, S., ... SCD‐I working group (2019). Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. Alzheimer's & Dementia, 15(3), 465-476. https://doi.org/10.1016/j.jalz.2018.10.003

@article{eeff25a92e6b4f00bf96dec8864fb523,

title = "Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia",

abstract = "Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia.Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models.Results: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini-Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E epsilon 4 (1.8 [1.3-2.5]) increased the risk of dementia.Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts. (C) 2018 The Authors. Published by Elsevier Inc.",

keywords = "Subjective cognitive decline, Dementia incidence, Preclinical Alzheimer's disease, Alzheimer's disease, Vascular dementia, Frontotemporal dementia, Dementia Lewy bodies, BASE-LINE CHARACTERISTICS, MEMORY COMPLAINTS, ASSOCIATION WORKGROUPS, DIAGNOSTIC GUIDELINES, NATIONAL INSTITUTE, RECRUITMENT METHODS, APOLIPOPROTEIN-E, MAJOR SUBTYPES, OLDER-ADULTS, IMPAIRMENT",

author = "Slot, {Rosalinde E. R.} and Sikkes, {Sietske A. M.} and Johannes Berkhof and Henry Brodaty and Rachel Buckley and Enrica Cavedo and Efthimios Dardiotis and Francoise Guillo-Benarous and Harald Hampel and Kochan, {Nicole A.} and Simone Lista and Tobias Luck and Paul Maruff and Molinuevo, {Jose Luis} and Johannes Kornhuber and Barry Reisberg and Riedel-Heller, {Steffi G.} and Risacher, {Shannon L.} and Susanne Roehr and Sachdev, {Perminder S.} and Nikolaos Scarmeas and Philip Scheltens and Shulman, {Melanie B.} and Saykin, {Andrew J.} and Verfaillie, {Sander C. J.} and Visser, {Pieter Jelle} and Vos, {Stephanie J. B.} and Michael Wagner and Steffen Wolfsgruber and Frank Jessen and {van der Flier}, {Wiesje M.} and {Alzheimer's Disease Neuroimaging Initiative} and {DESCRIPA working group} and {Insight-PreAD Study Grp} and {SCD‐I working group}",

note = "Funding Information: This Manuscript benefited from the support of the Program “PHOENIX” led by the Sorbonne University Foundation and sponsored by la Fondation pour la Recherche sur Alzheimer. Funding Information: Dr. Barry Reisberg's work on the project was supported in part by United States Department of Health and Human Services (DHHS) grants AG08051 and AG03051 for the National Institute on Aging, of the US National Institutes of Health, and by the Hagedorn Fund, the Stringer Foundation, the Louis J. Kay and June E. Kay Foundation, donations from Mrs. Miriam Glanbach and Dr. Felix Glanbach, and by a Clinical Research Development Fund of the New York University School of Medicine. A. Saykin and the Indiana Memory and Aging Study (IMAS) were supported by grants from the National Institute on Aging (P30 AG010133, R01 AG019771); S. Risacher was additionally supported by NIA K01 AG049050. ADNI data and sharing were funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace, Inc., Merck & Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Synarc Inc., and Takeda Pharmaceutical Company. Funding Information: The HELIAD study has been supported by the following grants: IIRG-09-133014 from the Alzheimer's Association; 189 10276/8/9/2011 from the ESPA-EU program Excellence Grant (ARISTEIA), which is cofunded by the European Social Fund and Greek National resources, DY2b/oij.51657/14.4.2009 from the Ministry for Health and Social Solidarity (Greece). Funding Information: S. Vos receives research support from ZonMw . The DESCRIPA study was supported by the European Commission within the 5th Framework Program, contract number QLK-6-CT-2002-02455. The German DCN study has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420). Funding Information: Disclosures: R.E.R.S., J.B., R.B., E.C., E.D., F.G.-B., N.A.K., T.L., P.M., J.L.M., J.K., B.R., S.G.R.-H., S.L.R., S.R., P.S.S., N.S., M.B.S., S.C.J.V., S.J.B.V., M.W., S.W., and F.J. report no conflicts of interest. All authors report no conflict of interest with the content of the present manuscript. In the last 3 years, H.B. has worked on a drug trial for patients with MCI and Alzheimer's disease sponsored by Tau Therapeutics and has been a consultant or advisory board member for Eli Lilly and Nutricia. H.H. serves as Senior Associate Editor for the Journal Alzheimer's & Dementia; he received lecture fees from Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to the institution), travel funding from Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics, consultancy fees from Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics, and Functional Neuromodulation, and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics; he is coinventor of patent applications and has received no royalties. S.L. received lecture honoraria from Roche. P.S. has received grant support for the institution Alzheimer Center, VU University Medical Center from GE Healthcare and MERCK; he has received speaker's fees paid to the institution Alzheimer Center, VU University Medical Center, from Lilly, GE Healthcare and Roche. S.A.M.S. provided consultancy services in the past 2 years for Nutricia and Takeda. All fees were paid to her institution. W.M.v.d.F. has received research funding and speaker honorarium from Boehringer Ingelheim and Biogen Inc. Research programs of W.M.v.d.F. have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, CardioVasculair Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis Fonds, Pasman Stichting, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, Biogen, Combinostics. All funding is paid to her institution. A.J.S. received research support from a collaborative grant from Eli Lilly during the time this project was completed, co-led an NIA SBIR grant with Arkley Biotek, and received PET tracer precursor assistance from Avid Radiopharmaceuticals.This work was supported by the Alzheimer's Association and the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Subjective Cognitive Decline Professional Interest Area (PIA). The authors are grateful to Keith Fargo and April Ross (ISTAART) for facilitating SCD PIA meetings.R. Slot and S. Verfaillie are supported by a research grant from Gieske-Strijbis Fonds. W.M. van der Flier holds the Pasman chair. F. Jessen and S. Sikkes is recipient of JPND - EURO-SCD (grant no: JPND_PS_FP-689-019). The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc fonds. The authors thank the collaborators from the DESCRIPA study for their work in the collection of the data. The DESCRIPA study group members include the following individuals: Merc? Boada, Fundaci? ACE, Barcelona, Spain; Peter Paul de Deyn, Institute Born Bunge, ZNA Middelheim, University of Antwerp, Antwerp, Belgium; Roy Jones, The Research Institute for the Care of Older People, Bath, UK; Giovanni Frisoni, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, and University Hospital and University of Geneva, Geneva, Switzerland; Luiza Spiru, ?Carol Davila? University of Medicine and Pharmacy, Bucharest, Romania; Flavio Nobili, Clinical Neurophysiology Service, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy; Yvonne Freund-Levi, Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Hilkka Soininen, Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter, Neurology, Kuopio University; Frans Verhey, Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands; ?sa K. Wallin, Lund University, Clinical Sciences Malm? Clinical Memory Research Unit, Lund, Sweden; Jacques Touchon, Institute National de la Sant? et de la Recherche Medicinale INSERM U 888, Montpellier, France; Marcel Olde Rikkert, Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; Anne-Sophie Rigaud, Department of Geriatrics, Hopital Broca, Paris, France; Roger Bullock, Kingshill Research Centre, Swindon, UK; Magda Tsolaki, Aristotle University of Thessaloniki, Memory and Dementia Center, 3rd Department of Neurology, ?G Papanicolaou? General Hospital, Thessaloniki, Greece; Bruno Vellas, Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France; Gordon Wilcock, Department of Care of Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; Harald Hampel, Universit? Pierre et Marie Curie-Paris 6, AP-HP, Hopital de la Salpetri?re, Paris, France; Lutz Froelich, Department of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.S. Vos receives research support from ZonMw. The DESCRIPA study was supported by the European Commission within the 5th Framework Program, contract number QLK-6-CT-2002-02455. The German DCN study has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420).The INSIGHT-preAD study was promoted by INSERM in collaboration with ICM, IHU-A-ICM and Pfizer and has received support within the ?Investissement d'Avenir? (ANR-10-AIHU-06) program. The study was promoted in collaboration with the ?CHU de Bordeaux? (coordination CIC EC7), the promoter of Memento cohort, funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/Lilly. H. Hampel is supported by the AXA Research Fund, the ?Fondation partenariale Sorbonne Universit?? and the ?Fondation pour la Recherche sur Alzheimer? Paris, France. Ce travail a b?n?fici? d'une aide de l'Etat ?Investissements d'avenir? ANR-10-IAIHU-06. The research leading to these results has received funding from the program ?Investissements d'avenir? ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Agence Institut Hospitalo-Universitaire-6).Dr. Barry Reisberg's work on the project was supported in part by United States Department of Health and Human Services (DHHS) grants AG08051 and AG03051 for the National Institute on Aging, of the US National Institutes of Health, and by the Hagedorn Fund, the Stringer Foundation, the Louis J. Kay and June E. Kay Foundation, donations from Mrs. Miriam Glanbach and Dr. Felix Glanbach, and by a Clinical Research Development Fund of the New York University School of Medicine. A. Saykin and the Indiana Memory and Aging Study (IMAS) were supported by grants from the National Institute on Aging (P30 AG010133, R01 AG019771); S. Risacher was additionally supported by NIA K01 AG049050. ADNI data and sharing were funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace, Inc., Merck & Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Synarc Inc., and Takeda Pharmaceutical Company. Funding Information: The INSIGHT-preAD study was promoted by INSERM in collaboration with ICM , IHU-A-ICM and Pfizer and has received support within the “Investissement d'Avenir” (ANR-10-AIHU-06) program. The study was promoted in collaboration with the “CHU de Bordeaux” (coordination CIC EC7), the promoter of Memento cohort, funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/ Lilly . H. Hampel is supported by the AXA Research Fund , the “Fondation partenariale Sorbonne Universit{\'e}” and the “Fondation pour la Recherche sur Alzheimer”, Paris, France. Ce travail a b{\'e}n{\'e}fici{\'e} d'une aide de l'Etat “Investissements d'avenir” ANR-10-IAIHU-06. The research leading to these results has received funding from the program “Investissements d'avenir” ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Agence Institut Hospitalo-Universitaire-6). Funding Information: R. Slot and S. Verfaillie are supported by a research grant from Gieske-Strijbis Fonds. W.M. van der Flier holds the Pasman chair. F. Jessen and S. Sikkes is recipient of JPND - EURO-SCD (grant no: JPND_PS_FP-689-019). The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc fonds. The authors thank the collaborators from the DESCRIPA study for their work in the collection of the data. The DESCRIPA study group members include the following individuals: Merc{\`e} Boada, Fundaci{\'o} ACE, Barcelona, Spain; Peter Paul de Deyn, Institute Born Bunge, ZNA Middelheim, University of Antwerp, Antwerp, Belgium; Roy Jones, The Research Institute for the Care of Older People, Bath, UK; Giovanni Frisoni, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, and University Hospital and University of Geneva, Geneva, Switzerland; Luiza Spiru, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Flavio Nobili, Clinical Neurophysiology Service, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy; Yvonne Freund-Levi, Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Hilkka Soininen, Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter, Neurology, Kuopio University; Frans Verhey, Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands; {\AA}sa K. Wallin, Lund University, Clinical Sciences Malm{\"o}, Clinical Memory Research Unit, Lund, Sweden; Jacques Touchon, Institute National de la Sant{\'e} et de la Recherche Medicinale INSERM U 888, Montpellier, France; Marcel Olde Rikkert, Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; Anne-Sophie Rigaud, Department of Geriatrics, Hopital Broca, Paris, France; Roger Bullock, Kingshill Research Centre, Swindon, UK; Magda Tsolaki, Aristotle University of Thessaloniki, Memory and Dementia Center, 3rd Department of Neurology, “G Papanicolaou” General Hospital, Thessaloniki, Greece; Bruno Vellas, Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France; Gordon Wilcock, Department of Care of Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; Harald Hampel, Universit{\'e} Pierre et Marie Curie-Paris 6, AP-HP, Hopital de la Salpetri{\`e}re, Paris, France; Lutz Froelich, Department of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg, Mannheim, Germany. Funding Information: This work was supported by the Alzheimer's Association and the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Subjective Cognitive Decline Professional Interest Area (PIA). The authors are grateful to Keith Fargo and April Ross (ISTAART) for facilitating SCD PIA meetings. Funding Information: N.A. Kochan and the Sydney Memory and Ageing Study were supported by grants from the National Health and Medical Research Center, Australia (350833, 1053804). Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2019",

month = mar,

doi = "10.1016/j.jalz.2018.10.003",

language = "English",

volume = "15",

pages = "465--476",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier Science",

number = "3",

}

Slot, RER, Sikkes, SAM, Berkhof, J, Brodaty, H, Buckley, R, Cavedo, E, Dardiotis, E, Guillo-Benarous, F, Hampel, H, Kochan, NA, Lista, S, Luck, T, Maruff, P, Molinuevo, JL, Kornhuber, J, Reisberg, B, Riedel-Heller, SG, Risacher, SL, Roehr, S, Sachdev, PS, Scarmeas, N, Scheltens, P, Shulman, MB, Saykin, AJ, Verfaillie, SCJ, Visser, PJ , Vos, SJB, Wagner, M, Wolfsgruber, S, Jessen, F, van der Flier, WM, Alzheimer's Disease Neuroimaging Initiative, DESCRIPA working group, Insight-PreAD Study Grp & SCD‐I working group 2019, 'Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia', Alzheimer's & Dementia, vol. 15, no. 3, pp. 465-476. https://doi.org/10.1016/j.jalz.2018.10.003

TY - JOUR

T1 - Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

AU - Slot, Rosalinde E. R.

AU - Sikkes, Sietske A. M.

AU - Berkhof, Johannes

AU - Brodaty, Henry

AU - Buckley, Rachel

AU - Cavedo, Enrica

AU - Dardiotis, Efthimios

AU - Guillo-Benarous, Francoise

AU - Hampel, Harald

AU - Kochan, Nicole A.

AU - Lista, Simone

AU - Luck, Tobias

AU - Maruff, Paul

AU - Molinuevo, Jose Luis

AU - Kornhuber, Johannes

AU - Reisberg, Barry

AU - Riedel-Heller, Steffi G.

AU - Risacher, Shannon L.

AU - Roehr, Susanne

AU - Sachdev, Perminder S.

AU - Scarmeas, Nikolaos

AU - Scheltens, Philip

AU - Shulman, Melanie B.

AU - Saykin, Andrew J.

AU - Verfaillie, Sander C. J.

AU - Visser, Pieter Jelle

AU - Vos, Stephanie J. B.

AU - Wagner, Michael

AU - Wolfsgruber, Steffen

AU - Jessen, Frank

AU - van der Flier, Wiesje M.

AU - Alzheimer's Disease Neuroimaging Initiative

AU - DESCRIPA working group

AU - Insight-PreAD Study Grp

AU - SCD‐I working group

N1 - Funding Information: This Manuscript benefited from the support of the Program “PHOENIX” led by the Sorbonne University Foundation and sponsored by la Fondation pour la Recherche sur Alzheimer. Funding Information: Dr. Barry Reisberg's work on the project was supported in part by United States Department of Health and Human Services (DHHS) grants AG08051 and AG03051 for the National Institute on Aging, of the US National Institutes of Health, and by the Hagedorn Fund, the Stringer Foundation, the Louis J. Kay and June E. Kay Foundation, donations from Mrs. Miriam Glanbach and Dr. Felix Glanbach, and by a Clinical Research Development Fund of the New York University School of Medicine. A. Saykin and the Indiana Memory and Aging Study (IMAS) were supported by grants from the National Institute on Aging (P30 AG010133, R01 AG019771); S. Risacher was additionally supported by NIA K01 AG049050. ADNI data and sharing were funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace, Inc., Merck & Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Synarc Inc., and Takeda Pharmaceutical Company. Funding Information: The HELIAD study has been supported by the following grants: IIRG-09-133014 from the Alzheimer's Association; 189 10276/8/9/2011 from the ESPA-EU program Excellence Grant (ARISTEIA), which is cofunded by the European Social Fund and Greek National resources, DY2b/oij.51657/14.4.2009 from the Ministry for Health and Social Solidarity (Greece). Funding Information: S. Vos receives research support from ZonMw . The DESCRIPA study was supported by the European Commission within the 5th Framework Program, contract number QLK-6-CT-2002-02455. The German DCN study has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420). Funding Information: Disclosures: R.E.R.S., J.B., R.B., E.C., E.D., F.G.-B., N.A.K., T.L., P.M., J.L.M., J.K., B.R., S.G.R.-H., S.L.R., S.R., P.S.S., N.S., M.B.S., S.C.J.V., S.J.B.V., M.W., S.W., and F.J. report no conflicts of interest. All authors report no conflict of interest with the content of the present manuscript. In the last 3 years, H.B. has worked on a drug trial for patients with MCI and Alzheimer's disease sponsored by Tau Therapeutics and has been a consultant or advisory board member for Eli Lilly and Nutricia. H.H. serves as Senior Associate Editor for the Journal Alzheimer's & Dementia; he received lecture fees from Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to the institution), travel funding from Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics, consultancy fees from Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics, and Functional Neuromodulation, and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics; he is coinventor of patent applications and has received no royalties. S.L. received lecture honoraria from Roche. P.S. has received grant support for the institution Alzheimer Center, VU University Medical Center from GE Healthcare and MERCK; he has received speaker's fees paid to the institution Alzheimer Center, VU University Medical Center, from Lilly, GE Healthcare and Roche. S.A.M.S. provided consultancy services in the past 2 years for Nutricia and Takeda. All fees were paid to her institution. W.M.v.d.F. has received research funding and speaker honorarium from Boehringer Ingelheim and Biogen Inc. Research programs of W.M.v.d.F. have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, CardioVasculair Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis Fonds, Pasman Stichting, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, Biogen, Combinostics. All funding is paid to her institution. A.J.S. received research support from a collaborative grant from Eli Lilly during the time this project was completed, co-led an NIA SBIR grant with Arkley Biotek, and received PET tracer precursor assistance from Avid Radiopharmaceuticals.This work was supported by the Alzheimer's Association and the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Subjective Cognitive Decline Professional Interest Area (PIA). The authors are grateful to Keith Fargo and April Ross (ISTAART) for facilitating SCD PIA meetings.R. Slot and S. Verfaillie are supported by a research grant from Gieske-Strijbis Fonds. W.M. van der Flier holds the Pasman chair. F. Jessen and S. Sikkes is recipient of JPND - EURO-SCD (grant no: JPND_PS_FP-689-019). The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc fonds. The authors thank the collaborators from the DESCRIPA study for their work in the collection of the data. The DESCRIPA study group members include the following individuals: Merc? Boada, Fundaci? ACE, Barcelona, Spain; Peter Paul de Deyn, Institute Born Bunge, ZNA Middelheim, University of Antwerp, Antwerp, Belgium; Roy Jones, The Research Institute for the Care of Older People, Bath, UK; Giovanni Frisoni, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, and University Hospital and University of Geneva, Geneva, Switzerland; Luiza Spiru, ?Carol Davila? University of Medicine and Pharmacy, Bucharest, Romania; Flavio Nobili, Clinical Neurophysiology Service, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy; Yvonne Freund-Levi, Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Hilkka Soininen, Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter, Neurology, Kuopio University; Frans Verhey, Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands; ?sa K. Wallin, Lund University, Clinical Sciences Malm? Clinical Memory Research Unit, Lund, Sweden; Jacques Touchon, Institute National de la Sant? et de la Recherche Medicinale INSERM U 888, Montpellier, France; Marcel Olde Rikkert, Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; Anne-Sophie Rigaud, Department of Geriatrics, Hopital Broca, Paris, France; Roger Bullock, Kingshill Research Centre, Swindon, UK; Magda Tsolaki, Aristotle University of Thessaloniki, Memory and Dementia Center, 3rd Department of Neurology, ?G Papanicolaou? General Hospital, Thessaloniki, Greece; Bruno Vellas, Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France; Gordon Wilcock, Department of Care of Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; Harald Hampel, Universit? Pierre et Marie Curie-Paris 6, AP-HP, Hopital de la Salpetri?re, Paris, France; Lutz Froelich, Department of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.S. Vos receives research support from ZonMw. The DESCRIPA study was supported by the European Commission within the 5th Framework Program, contract number QLK-6-CT-2002-02455. The German DCN study has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420).The INSIGHT-preAD study was promoted by INSERM in collaboration with ICM, IHU-A-ICM and Pfizer and has received support within the ?Investissement d'Avenir? (ANR-10-AIHU-06) program. The study was promoted in collaboration with the ?CHU de Bordeaux? (coordination CIC EC7), the promoter of Memento cohort, funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/Lilly. H. Hampel is supported by the AXA Research Fund, the ?Fondation partenariale Sorbonne Universit?? and the ?Fondation pour la Recherche sur Alzheimer? Paris, France. Ce travail a b?n?fici? d'une aide de l'Etat ?Investissements d'avenir? ANR-10-IAIHU-06. The research leading to these results has received funding from the program ?Investissements d'avenir? ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Agence Institut Hospitalo-Universitaire-6).Dr. Barry Reisberg's work on the project was supported in part by United States Department of Health and Human Services (DHHS) grants AG08051 and AG03051 for the National Institute on Aging, of the US National Institutes of Health, and by the Hagedorn Fund, the Stringer Foundation, the Louis J. Kay and June E. Kay Foundation, donations from Mrs. Miriam Glanbach and Dr. Felix Glanbach, and by a Clinical Research Development Fund of the New York University School of Medicine. A. Saykin and the Indiana Memory and Aging Study (IMAS) were supported by grants from the National Institute on Aging (P30 AG010133, R01 AG019771); S. Risacher was additionally supported by NIA K01 AG049050. ADNI data and sharing were funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace, Inc., Merck & Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Synarc Inc., and Takeda Pharmaceutical Company. Funding Information: The INSIGHT-preAD study was promoted by INSERM in collaboration with ICM , IHU-A-ICM and Pfizer and has received support within the “Investissement d'Avenir” (ANR-10-AIHU-06) program. The study was promoted in collaboration with the “CHU de Bordeaux” (coordination CIC EC7), the promoter of Memento cohort, funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/ Lilly . H. Hampel is supported by the AXA Research Fund , the “Fondation partenariale Sorbonne Université” and the “Fondation pour la Recherche sur Alzheimer”, Paris, France. Ce travail a bénéficié d'une aide de l'Etat “Investissements d'avenir” ANR-10-IAIHU-06. The research leading to these results has received funding from the program “Investissements d'avenir” ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Agence Institut Hospitalo-Universitaire-6). Funding Information: R. Slot and S. Verfaillie are supported by a research grant from Gieske-Strijbis Fonds. W.M. van der Flier holds the Pasman chair. F. Jessen and S. Sikkes is recipient of JPND - EURO-SCD (grant no: JPND_PS_FP-689-019). The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc fonds. The authors thank the collaborators from the DESCRIPA study for their work in the collection of the data. The DESCRIPA study group members include the following individuals: Mercè Boada, Fundació ACE, Barcelona, Spain; Peter Paul de Deyn, Institute Born Bunge, ZNA Middelheim, University of Antwerp, Antwerp, Belgium; Roy Jones, The Research Institute for the Care of Older People, Bath, UK; Giovanni Frisoni, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, and University Hospital and University of Geneva, Geneva, Switzerland; Luiza Spiru, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Flavio Nobili, Clinical Neurophysiology Service, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy; Yvonne Freund-Levi, Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Hilkka Soininen, Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter, Neurology, Kuopio University; Frans Verhey, Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands; Åsa K. Wallin, Lund University, Clinical Sciences Malmö, Clinical Memory Research Unit, Lund, Sweden; Jacques Touchon, Institute National de la Santé et de la Recherche Medicinale INSERM U 888, Montpellier, France; Marcel Olde Rikkert, Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; Anne-Sophie Rigaud, Department of Geriatrics, Hopital Broca, Paris, France; Roger Bullock, Kingshill Research Centre, Swindon, UK; Magda Tsolaki, Aristotle University of Thessaloniki, Memory and Dementia Center, 3rd Department of Neurology, “G Papanicolaou” General Hospital, Thessaloniki, Greece; Bruno Vellas, Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France; Gordon Wilcock, Department of Care of Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; Harald Hampel, Université Pierre et Marie Curie-Paris 6, AP-HP, Hopital de la Salpetrière, Paris, France; Lutz Froelich, Department of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg, Mannheim, Germany. Funding Information: This work was supported by the Alzheimer's Association and the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Subjective Cognitive Decline Professional Interest Area (PIA). The authors are grateful to Keith Fargo and April Ross (ISTAART) for facilitating SCD PIA meetings. Funding Information: N.A. Kochan and the Sydney Memory and Ageing Study were supported by grants from the National Health and Medical Research Center, Australia (350833, 1053804). Publisher Copyright: © 2018 The Authors

PY - 2019/3

Y1 - 2019/3

N2 - Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia.Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models.Results: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini-Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E epsilon 4 (1.8 [1.3-2.5]) increased the risk of dementia.Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts. (C) 2018 The Authors. Published by Elsevier Inc.

AB - Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia.Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models.Results: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini-Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E epsilon 4 (1.8 [1.3-2.5]) increased the risk of dementia.Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts. (C) 2018 The Authors. Published by Elsevier Inc.

KW - Subjective cognitive decline

KW - Dementia incidence

KW - Preclinical Alzheimer's disease

KW - Alzheimer's disease

KW - Vascular dementia

KW - Frontotemporal dementia

KW - Dementia Lewy bodies

KW - BASE-LINE CHARACTERISTICS

KW - MEMORY COMPLAINTS

KW - ASSOCIATION WORKGROUPS

KW - DIAGNOSTIC GUIDELINES

KW - NATIONAL INSTITUTE

KW - RECRUITMENT METHODS

KW - APOLIPOPROTEIN-E

KW - MAJOR SUBTYPES

KW - OLDER-ADULTS

KW - IMPAIRMENT

U2 - 10.1016/j.jalz.2018.10.003

DO - 10.1016/j.jalz.2018.10.003

M3 - Article

SN - 1552-5260

VL - 15

SP - 465

EP - 476

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 3

ER -

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Abstract

Keywords

Access to Document

Fingerprint

Cite this